Clinical Trial Update: Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial update evaluating safety, tolerability, and preliminary efficacy of JK1201I in patients with Small Cell Lung Cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• JK1201I

Snippet

Sponsor: JenKem Technology Co., Ltd. | Conditions: Small Cell Lung Cancer (SCLC) | Phase 1, Phase 2 | Status: UNKNOWN